ClinicalTrials.gg
RecruitingNCT07493668FLEX-HCCUpdated May 22, 2026

Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy

A Phase 2 interventional study of Fostrox and Lenvatinib in Hepatocellular Carcinoma (HCC), sponsored by CHA University. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by CHA University · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 298 studies in Carcinoma, Hepatocellular with a site in Korea, Republic of — 50 open to participants now, 74 under way, 8 of them phase 3. Carcinoma, Hepatocellular · Korea, Republic of.

Planned enrollment
135th of 255
80 · median 87
Started
2026
with 10 others
Phase 2
85 of 298
16 open now
Primary completion
2028-04
later than 56 of 73 live
Registered
293rd of 298
by date
Lead sponsor
6 of 298
CHA University

Among the 298 studies in Carcinoma, Hepatocellular with a site in Korea, Republic of, this one is the 135th largest by planned enrollment of the 255 interventional ones that give a count, is one of 11 that started in 2026, is one of 85 in phase 2, reaches primary completion later than 56 of the 73 other live ones, and was the 293rd registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

50 of the 298 studies in Carcinoma, Hepatocellular with a site in Korea, Republic of are open now. Recruiting first, the newest first:

44 more — sign in →

All 50 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 298 studies in Carcinoma, Hepatocellular with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This is a Phase 2, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of fostrox in combination with lenvatinib compared with lenvatinib alone in patients with locally advanced or unresectable advanced hepatocellular carcinoma (HCC) who have experienced radiologically confirmed disease progression following first-line combination immunotherapy.

Approximately 80 patients will be enrolled at 9 study sites and randomized in a 1:1 ratio to 1 of 2 treatment arms: fostrox plus lenvatinib or lenvatinib alone. Patients assigned to the investigational arm will receive fostrox orally once daily on Days 1 through 5 of each 21-day cycle in combination with continuous daily lenvatinib. Patients assigned to the control arm will receive lenvatinib alone according to the approved weight-based dosing regimen. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-defined discontinuation criteria are met.

The study population includes adult patients with locally advanced or unresectable metastatic HCC who have received at least 2 cycles of first-line systemic therapy with an immunotherapy combination and have radiologically confirmed disease progression. Eligible patients must have measurable disease according to RECIST version 1.1 and mRECIST, adequate organ function, and Child-Pugh class A liver function.

The primary objective is to assess objective response rate (ORR) as determined by an Independent Review Facility (IRF) according to RECIST v1.1. Secondary objectives include evaluation of ORR by investigator assessment according to RECIST v1.1 and mRECIST, duration of response, disease control rate, progression-free survival, time to progression, overall survival, and safety and tolerability. Safety evaluations will include assessment of adverse events, serious adverse events, laboratory parameters, vital signs, and other clinical assessments. Exploratory objectives include evaluation of peripheral blood-based biomarkers, metabolic changes associated with study treatment, collection and storage of DNA and RNA for exploratory analyses, and pharmacokinetic assessment of fostrox and its metabolite troxacitabine in patients receiving fostrox in combination with lenvatinib.

Tumor assessments will be performed at protocol-defined intervals using radiologic imaging. The primary efficacy analysis will be based on IRF assessment according to RECIST v1.1. This study is intended to characterize the clinical activity and safety profile of fostrox plus lenvatinib compared with lenvatinib alone in this patient population and to generate data to inform future clinical development.

Read the detailed description

Hepatocellular carcinoma (HCC) is the predominant histologic subtype of primary liver cancer and remains associated with poor clinical outcomes, particularly in patients with locally advanced or unresectable disease. In recent years, first-line treatment for advanced HCC has shifted from tyrosine kinase inhibitors (TKIs) to immune checkpoint inhibitor-based combination regimens. Although these regimens have improved outcomes for some patients, a substantial proportion of patients experience disease progression and require second-line treatment. In this setting, there are limited prospective data to guide treatment selection, and additional therapeutic options are needed.

Fostrox is an orally administered, liver-directed prodrug of troxacitabine monophosphate designed to enhance delivery of active metabolite to the liver while limiting systemic exposure. Following intracellular activation, fostrox generates metabolites that are retained within cells, including the active metabolite troxacitabine triphosphate, which is incorporated into DNA during replication and leads to DNA chain termination, DNA damage responses, and cytotoxicity. This liver-directed mechanism is intended to maximize exposure in hepatic tissue and reduce off-target toxicity. Lenvatinib is a multikinase inhibitor with antiangiogenic and antitumor activity and is widely used in the management of advanced HCC. Based on their distinct and potentially complementary mechanisms of action, the combination of fostrox and lenvatinib may provide additional clinical benefit in patients whose disease has progressed after first-line combination immunotherapy.

This study is a multicenter, randomized, open-label Phase 2 trial evaluating fostrox plus lenvatinib versus lenvatinib alone in patients with locally advanced or unresectable advanced HCC previously treated with first-line combination immunotherapy. The study is designed as a proof-of-concept trial to assess the relative clinical benefit and safety profile of the combination regimen and to inform future development decisions. Approximately 80 patients will be randomized in a 1:1 ratio to receive either fostrox plus lenvatinib or lenvatinib alone.

Patients assigned to the investigational arm will receive fostrox orally once daily on Days 1 through 5 of each 21-day cycle together with continuous daily lenvatinib administered according to the approved weight-based dosing regimen. Patients assigned to the control arm will receive lenvatinib alone. Randomization will be stratified according to prior treatment category, presence or absence of extrahepatic spread and/or macrovascular invasion, and alpha-fetoprotein level greater than 400 ng/mL.

The study population includes adult patients with radiologically, histologically, or cytologically confirmed locally advanced or unresectable metastatic HCC who have received at least 2 cycles of first-line systemic therapy with an immunotherapy combination and have radiologically confirmed disease progression. Patients must have measurable disease, adequate hematologic and hepatic function, and Child-Pugh class A liver function. Key exclusion criteria include prior exposure to TKI-containing immunotherapy combinations, central nervous system metastasis, major uncontrolled cardiovascular disease, clinically significant uncontrolled hypertension, clinically significant ascites, active hepatic encephalopathy, certain bleeding or thrombotic conditions, and other medical conditions that could interfere with study participation or interpretation of results.

The primary endpoint is objective response rate as assessed by an Independent Review Facility according to RECIST version 1.1. Secondary efficacy endpoints include investigator-assessed objective response rate according to RECIST v1.1 and mRECIST, duration of response, disease control rate, progression-free survival, time to progression, and overall survival. Safety and tolerability will be assessed throughout the study by monitoring adverse events, serious adverse events, laboratory abnormalities, and clinical findings. Exploratory evaluations will include peripheral blood-based biomarker analyses, metabolic assessments, collection and storage of DNA and RNA for exploratory research, and pharmacokinetic assessment of fostrox and its metabolite troxacitabine in patients receiving the combination regimen.

Tumor imaging will be performed at protocol-defined intervals, and response assessments will be conducted using standardized radiologic criteria. Independent radiologic review will be incorporated to support objectivity in efficacy evaluation. This study is intended to further characterize the antitumor activity and safety of fostrox in combination with lenvatinib in a second-line advanced HCC population following prior combination immunotherapy.

03

Conditions studied

  • Hepatocellular Carcinoma (HCC)

Keywords

  • HCC
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with a diagnosis of locally advanced or unresectable HCC confirmed by radiology, histology, or cytology
  2. Received at least 2 cycles of systemic therapy with immunotherapy (IO) combination (atezolizumab + bevacizumab, ipilimumab + nivolumab, or durvalumab + tremelimumab), with radiologically confirmed disease progression
  3. Patients with in the liver (at least one target lesion) according to v1.1 and

    - Patients who received prior local therapy (e.g., radiofrequency ablation, cryoablation, percutaneous ethanol or acetic acid injection, high-intensity focused ultrasound, transarterial chemoembolization, or transarterial embolization) are eligible provided the target lesion(s) have not been previously treated with local therapy or the target lesion(s) within the field of local therapy have subsequently progressed in accordance with RECIST v1.1

  4. Patients who are not amenable for curative surgery or locoregional therapy
  5. performance status of 0 or 1 within 7 days prior to randomization
  6. of at least 3 months
  7. Subjects age ≥19 years at the time of signing the form (ICF)
  8. Subjects who are capable of providing signed informed consent to comply with requirements and limitations described in the ICF and this protocol and express obvious and voluntary agreement prior to the start of the study
  9. Subjects with adequate hematological function and hepatic function without using blood transfusion or growth factors within 7 days prior to randomization

    • (Hb) ≥9.0 g/dL
    • (ANC) ≥1,500/μl
    • count ≥75,000/μl
    • Serum creatinine ≤1.5 x (ULN) or (CrCl) estimated by Cockcroft-Gault equation ≥60 mL/min
    • (AST) and alanine aminotransferase (ALT) ≤5.0 x ULN
    • Serum total ≤3.0 x ULN
    • (INR) ≤1.5 or prothrombin time ≤1.5 x ULN
    • Activated partial thromboplastin time (aPTT) ≤1.5 x ULN
  10. A within 7 days prior to randomization
  11. Negative test at screening
  12. Documented hepatitis virus status for and confirmed at screening

    • For patients with active HBV: HBV DNA \<500 IU/mL during screening; initiation of antiviral therapy at least 14 days prior to randomization; willingness to continue antiviral therapy during the study
    • For patients with active or past HCV infection: confirmed negative viral load using HCV PCR
    • For patients with concurrent HBV and HCV infection: not eligible
  13. Resolution of any acute, treatment-related toxicity from prior therapy to Grade ≤1 before participation, except alopecia
  14. Patients with a prior history of gastric or esophageal variceal bleeding may be eligible if they have received appropriate treatment with no evidence of recurrent bleeding for at least 6 months, have no high-risk features on a recent endoscopy, and are currently assessed to be at low risk of bleeding.
  15. Female subjects

    • Eligible if
    • Female patient who is a woman of (WOCBP) (post menarchal) who agrees to use a highly efficient method of (a method with less than 1% failure rate [e.g. sterilization, hormone implants, hormone injections, intrauterine devices, vasectomized partner, or combined birth control pills]) from screening until at least 6 months after the last dose of study drug
    • WOCBP must have a negative urine pregnancy test at screening and negative urine pregnancy test within 72 hours before the first dose of study drug.
    • If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
    • Female patients must agree not to breast feed after the time of consent and for at least 6 months after the administration of the last dose of study drug.
  16. Male subjects

    • Male patient who has had a successful vasectomy (confirmed azoospermia)
    • Male patient agrees to use effective contraception, including condom use, from screening until at least 3 months after the last dose of study drug (no sperm donation is allowed during the study period and for at least 3 months after study drug discontinuation)
    • Male patient with a female partner who is a WOCBP and is using a highly efficient method of contraception as described above

Exclusion criteria

Exclusion Criteria:

  1. Patients who have received more than 1 prior systemic therapy (i.e., fostrox + lenvatinib or lenvatinib must be administered as treatment)
  2. Patients who have received first-line systemic therapy for locally advanced unresectable or HCC other than an IO combination
  3. Patients who have received a prior TKI (e.g. lenvatinib, regorafenib, cabozantinib etc.) in the IO combination
  4. Patients with a history of to lenvatinib or any of its components (active ingredient or )
  5. Patients with fibrolamellar HCC, sarcomoid HCC, or a mix of HCC and intrahepatic cholangiocarcinoma (iCCA)
  6. Patients with central nervous system metastasis
  7. Patients with VP4 portal vein tumor thrombosis (PVTT)
  8. Patients with significant cardiovascular disease within 3 months prior to randomization

    • (NYHA) Class III or IV congestive heart failure
    • Unstable angina
    • Myocardial infarction
    • Cardiac arrhythmia associated with hemodynamic instability
  9. Subjects with interval (QTcF) >470 msec at Screening (corrected by Fridericia Formula)
  10. Patients with prior allogeneic stem cell or solid organ transplantation
  11. Patients with systemic infection requiring treatment including active tuberculosis within 14 days prior to the first dose of study drug (prophylactic oral antibiotics are permitted)
  12. Major surgery within 3 weeks prior to randomization or scheduled for surgery during the study
  13. Patients with active within the past 36 months prior to randomization (except for completed resected basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in-situ, intramucosal carcinoma, superficial bladder cancer, or other cancers with no recurrence for ≥3 years)
  14. Patients with gastric or esophageal varices that require interventional treatment within 28 days prior to randomization. Prophylaxis with pharmacologic therapy (e.g. nonselective beta-blocker) is permitted.
  15. Patients with bleeding or thrombotic disorders or use of anticoagulants requiring therapeutic monitoring (e.g. warfarin etc.). Treatment with low molecular weight heparin and factor X inhibitors which do not require INR monitoring is permitted.
  16. Systolic blood pressure (BP) >160 mmHg or diastolic BP >100 mmHg despite optimal antihypertensive therapy, or uncontrolled without changes in antihypertensive agents within 1 week prior to screening
  17. Clinical ascites regardless of the severity (mild, moderate, or severe). Radiological ascites managed with diuretics and a low-sodium diet are accepted if the score is A.
  18. History of encephalopathy within the 6 months prior to randomization or current hepatic encephalopathy
  19. Receiving drugs that are extensively metabolized by that have a narrow therapeutic index must be discontinued 5 half-lives before the first dose of study drug (fostrox). Information on CYP3A4 was referenced from the following websites:

    • CredibleMeds (https://crediblemeds.org)
    • DrugBank (https://go.drugbank.com/categories/DBCAT002646)
  20. Receiving drugs that are strong inhibitors of P-glycoprotein (P-gP) and/or breast cancer resistance protein (BCRP)
  21. Proteinuria as defined by urine protein ≥1 g/24 hours at screening. Patients having >2+ proteinuria on urine dipstick testing will undergo a 24 hour urine collection or urine protein-to-creatinine ratio (UPCR) test for quantitative assessment of proteinuria.
  22. Significant vascular disease (e.g. aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to initiation of study treatment
  23. Receiving anticancer therapy for HCC within 4 weeks prior to the first dose of study drug (fostrox)
  24. Receiving any other agent within 4 weeks prior to screening
  25. Enrolled in another clinical study with an investigational drug
  26. Are unable to swallow orally administered medication or have gastrointestinal disorders likely to interfere with absorption of the study drug
  27. Any other condition that precludes adequate understanding, cooperation, and compliance with study procedures or any condition that could pose a risk to the patient's safety, as per the investigator's judgment
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Fostrox + Lenvatinib

    Fostrox: Oral, once daily for 5 days (Day 1-5) followed by 16-day rest in a 21-day cycle. Lenvatinib: Oral daily, continuous; 12 mg QD (≥60 kg) or 8 mg QD (\<60 kg).

    Drug: Fostrox · Drug: Lenvatinib

  • Active comparator
    Lenvatinib

    Lenvatinib: Oral daily, continuous; 12 mg QD (≥60 kg) or 8 mg QD (\<60 kg)

    Drug: Lenvatinib

Interventions

  • DrugFostrox

    Fostrox is an orally administered troxacitabine monophosphate prodrug designed to achieve selective activation within hepatocytes. In this study, Fostrox is given once daily on Days 1-5 of each 21-day treatment cycle, followed by a 16-day rest period. On Cycle 1 Day 1, dosing occurs on-site; subsequent doses (Days 2-5) may be administered at home. Fostrox is taken on an empty stomach with approximately 200 mL of water, and food intake is allowed at least 1 hour after dosing.

  • Lenvatinib will be administered orally once daily on a continuous basis according to the approved weight-based dosing regimen. Patients weighing ≥60 kg will receive 12 mg once daily, and patients weighing \<60 kg will receive 8 mg once daily.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) by Independent Review Facility (IRF) According to RECIST v1.1

    Objective response rate (ORR) is defined as the proportion of participants with a best overall response of complete response (CR) or partial response (PR), as determined by an Independent Review Facility (IRF) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The primary efficacy analysis population is the Full Analysis Set (FAS), defined as all randomized participants who receive at least 1 dose of study treatment and undergo at least 1 post-baseline efficacy assessment.

    Time frame: From randomization until disease progression, withdrawal of consent, or end of study, whichever occurs first; assessed every 6 weeks from Cycle 1 Day 1 through Week 54 and every 9 weeks thereafter, up to approximately 36 months

Secondary outcomes

  1. Objective Response Rate (ORR) by Investigator According to RECIST v1.1

    ORR is defined as the proportion of participants with a best overall response of CR or PR, as assessed by the investigator according to RECIST v1.1.

    Time frame: From randomization until disease progression, withdrawal of consent, or end of study, whichever occurs first; assessed every 6 weeks from Cycle 1 Day 1 through Week 54 and every 9 weeks thereafter, up to approximately 36 months

  2. Objective Response Rate (ORR) by Investigator According to mRECIST

    ORR is defined as the proportion of participants with a best overall response of CR or PR, as assessed by the investigator according to modified RECIST (mRECIST).

    Time frame: From randomization until disease progression, withdrawal of consent, or end of study, whichever occurs first; assessed every 6 weeks from Cycle 1 Day 1 through Week 54 and every 9 weeks thereafter, up to approximately 36 months

  3. Duration of Response (DOR) by Investigator According to RECIST v1.1

    DOR is defined as the time from the first documented occurrence of CR or PR to the first documented disease progression or death from any cause, as assessed by the investigator according to RECIST v1.1, among participants who achieve CR or PR.

    Time frame: From first documented CR or PR until first documented disease progression or death from any cause, up to approximately 36 months

  4. Duration of Response (DOR) by Investigator According to mRECIST

    DOR is defined as the time from the first documented occurrence of CR or PR to the first documented disease progression or death from any cause, as assessed by the investigator according to mRECIST, among participants who achieve CR or PR.

    Time frame: From first documented CR or PR until first documented disease progression or death from any cause, up to approximately 36 months

  5. Disease Control Rate (DCR) by Investigator According to RECIST v1.1

    DCR is defined as the proportion of participants with a best overall response of CR, PR, or stable disease (SD), as assessed by the investigator according to RECIST v1.1.

    Time frame: From randomization until disease progression, withdrawal of consent, or end of study, whichever occurs first; assessed every 6 weeks from Cycle 1 Day 1 through Week 54 and every 9 weeks thereafter, up to approximately 36 months

  6. Disease Control Rate (DCR) by Investigator According to mRECIST

    DCR is defined as the proportion of participants with a best overall response of CR, PR, or SD, as assessed by the investigator according to mRECIST.

    Time frame: From randomization until disease progression, withdrawal of consent, or end of study, whichever occurs first; assessed every 6 weeks from Cycle 1 Day 1 through Week 54 and every 9 weeks thereafter, up to approximately 36 months

  7. Progression-Free Survival (PFS) by Investigator According to RECIST v1.1

    PFS is defined as the time from randomization to the first documented disease progression or death from any cause, as assessed by the investigator according to RECIST v1.1.

    Time frame: From randomization until first documented disease progression or death from any cause, up to approximately 36 months

  8. Progression-Free Survival (PFS) by Investigator According to mRECIST

    PFS is defined as the time from randomization to the first documented disease progression or death from any cause, as assessed by the investigator according to mRECIST.

    Time frame: From randomization until first documented disease progression or death from any cause, up to approximately 36 months

  9. Time to Progression (TTP) by Investigator According to RECIST v1.1

    TTP is defined as the time from randomization to the first documented disease progression, as assessed by the investigator according to RECIST v1.1. Death without prior documented progression will not be counted as a progression event.

    Time frame: From randomization until first documented disease progression, up to approximately 36 months

  10. Time to Progression (TTP) by Investigator According to mRECIST

    TTP is defined as the time from randomization to the first documented disease progression, as assessed by the investigator according to mRECIST. Death without prior documented progression will not be counted as a progression event.

    Time frame: From randomization until first documented disease progression, up to approximately 36 months

  11. Duration of Response (DOR) by Independent Review Facility (IRF) According to RECIST v1.1

    DOR is defined as the time from the first documented occurrence of CR or PR to the first documented disease progression or death from any cause, as assessed by an Independent Review Facility (IRF) according to RECIST v1.1, among participants who achieve CR or PR.

    Time frame: From first documented CR or PR until first documented disease progression or death from any cause, up to approximately 36 months

  12. Progression-Free Survival (PFS) by Independent Review Facility (IRF) According to RECIST v1.1

    PFS is defined as the time from randomization to the first documented disease progression or death from any cause, as assessed by an Independent Review Facility (IRF) according to RECIST v1.1.

    Time frame: From randomization until first documented disease progression or death from any cause, up to approximately 36 months

  13. Time to Progression (TTP) by Independent Review Facility (IRF) According to RECIST v1.1

    TTP is defined as the time from randomization to the first documented disease progression, as assessed by an Independent Review Facility (IRF) according to RECIST v1.1. Death without prior documented progression will not be counted as a progression event.

    Time frame: From randomization until first documented disease progression, up to approximately 36 months

  14. Overall Survival (OS)

    OS is defined as the time from randomization to death from any cause.

    Time frame: From randomization until death from any cause, up to approximately 36 months

  15. Incidence and Severity of Adverse Events

    Safety and tolerability will be assessed by evaluating the incidence, nature, and severity of adverse events (AEs) and serious adverse events (SAEs), graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.

    Time frame: From signing of informed consent until 28 days after the last dose of study drug, or until resolution/stabilization as clinically indicated, up to approximately 36 months

Other outcomes

  1. Percentage or Count of Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMCs)

    Evaluation of the baseline percentage or absolute count of specific immune cell subsets within PBMCs and subsequent changes following study drug administration to identify potential response factors.

    Time frame: Baseline (Cycle 1 Day 1), every 2 cycles up to Week 54, every 3 cycles thereafter, and at the End of Treatment visit.

  2. Percentage Change from Baseline in the Concentration of Targeted Blood Metabolites

    Evaluation of metabolic changes mediated by the study drug by measuring the percentage change from baseline in the concentration of targeted endogenous blood metabolites.

    Time frame: Baseline (Cycle 1 Day 1), every 2 cycles up to Week 54, every 3 cycles thereafter, and at the End of Treatment visit (estimated up to 36 months).

  3. Number of Participants with Specific Genetic Alterations Identified via ctDNA and RNA Sequencing

    Investigation of genetic alterations that may affect responses (i.e., distribution, safety, tolerability, and efficacy) to study treatment and/or susceptibility to diseases.

    Time frame: Baseline, every 2 cycles up to Week 54, every 3 cycles thereafter, and at the End of Treatment visit.

  4. Plasma Concentration of Fostrox and Troxacitabine

    Evaluation of the pharmacokinetics of troxacitabine (the metabolite of fostrox) by measuring whole blood plasma concentrations in participants receiving fostrox in combination with lenvatinib.

    Time frame: Cycle 1 Day 1 at 30 minutes, 1 hour, 2 hours, and 4 hours after fostrox administration

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Evans TRJ, Chon HJ, Kim DY, et al. (Poster) Final safety and efficacy results from the phase 1b/2a study of fostrox plus lenvatinib in second/third line patients with advanced hepatocellular carcinoma who progressed on immunotherapy. EASL Liver Cancer Summit. 2025.
  • Chon HJ, Heo J, Reig Monzon ME, et al. 176P - Liver pharmacodynamics in an open-label phase Ib/IIa study of fostroxacitabine bralpamide (fostrox, MIV-818) in combination with lenvatinib in 2L/3L hepatocellular carcinoma. Ann Oncol. 2024;35(S1):S80.
  • Oberg F, Bhoi S, Wallberg H, et al. PO-221 - Liver biopsy biomarkers in a phase 1 study of the prodrug MIV-818 demonstrates proof-of-concept for cancer in the liver. EASL. 2022.
  • Sarker D, Evans J, Van Cutsem, et al. 527P - Phase I study of the novel prodrug MIV-818 in patients with hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA) or liver metastases (LM). Ann Oncol. 2021;32(S5):S594.
  • Bethell R, Tunblad K, Rizoska B, et al. SAT-123 - Liver-targeting with the novel nucleotide prodrug MIV-818 designed for the treatment of liver cancers. EASL The International Liver Congress. 2017.
  • NCCN Guidelines 2023. NCCN Guidelines for Patients with Hepatocellular Carcinoma.
  • Choi SH, Kang I, Lee SH, Kang B, Cheon J, Kim DJ, Kim G, Kwon CI, Ko KH, Chon HJ. Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma. Surgery. 2023 Feb;173(2):280-288. doi: 10.1016/j.surg.2022.09.028. Epub 2022 Nov 23. PubMed 36435652 ↗
  • Lam W, Leung CH, Bussom S, Cheng YC. The impact of hypoxic treatment on the expression of phosphoglycerate kinase and the cytotoxicity of troxacitabine and gemcitabine. Mol Pharmacol. 2007 Sep;72(3):536-44. doi: 10.1124/mol.106.033472. Epub 2007 Jun 12. PubMed 17565005 ↗
  • Buttell A, Qiu W. The action and resistance mechanisms of Lenvatinib in liver cancer. Mol Carcinog. 2023 Dec;62(12):1918-1934. doi: 10.1002/mc.23625. Epub 2023 Sep 6. PubMed 37671815 ↗
  • Wu Q, Qin Y, Li Q. Nivolumab plus ipilimumab versus lenvatinib or sorafenib for US and Chinese patients with unresectable hepatocellular carcinoma: a cost-effectiveness analysis. Front Public Health. 2026 Jan 12;13:1726477. doi: 10.3389/fpubh.2025.1726477. eCollection 2025. PubMed 41602061 ↗
  • Grove KL, Cheng YC. Uptake and metabolism of the new anticancer compound beta-L-(-)-dioxolane-cytidine in human prostate carcinoma DU-145 cells. Cancer Res. 1996 Sep 15;56(18):4187-91. PubMed 8797590 ↗
  • Ewald B, Sampath D, Plunkett W. ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance. Cancer Res. 2008 Oct 1;68(19):7947-55. doi: 10.1158/0008-5472.CAN-08-0971. PubMed 18829552 ↗
  • Kukhanova M, Liu SH, Mozzherin D, Lin TS, Chu CK, Cheng YC. L- and D-enantiomers of 2',3'-dideoxycytidine 5'-triphosphate analogs as substrates for human DNA polymerases. Implications for the mechanism of toxicity. J Biol Chem. 1995 Sep 29;270(39):23055-9. doi: 10.1074/jbc.270.39.23055. PubMed 7559445 ↗
  • Gourdeau H, Leblond L, Hamelin B, Dong K, Ouellet F, Boudreau C, Custeau D, Richard A, Gilbert MJ, Jolivet J. Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development. Clin Cancer Res. 2004 Nov 15;10(22):7692-702. doi: 10.1158/1078-0432.CCR-04-0657. PubMed 15570003 ↗
  • Grove KL, Guo X, Liu SH, Gao Z, Chu CK, Cheng YC. Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration. Cancer Res. 1995 Jul 15;55(14):3008-11. PubMed 7606719 ↗
  • Gordan JD, Kennedy EB, Abou-Alfa GK, Beg MS, Brower ST, Gade TP, Goff L, Gupta S, Guy J, Harris WP, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb AO, Kelley RK, Knox JJ, Kortmansky J, Leaf A, Remak WM, Shroff RT, Sohal DPS, Taddei TH, Venepalli NK, Wilson A, Zhu AX, Rose MG. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. J Clin Oncol. 2020 Dec 20;38(36):4317-4345. doi: 10.1200/JCO.20.02672. Epub 2020 Nov 16. PubMed 33197225 ↗
  • Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1. PubMed 29433850 ↗
  • Sonbol MB, Riaz IB, Naqvi SAA, Almquist DR, Mina S, Almasri J, Shah S, Almader-Douglas D, Uson Junior PLS, Mahipal A, Ma WW, Jin Z, Mody K, Starr J, Borad MJ, Ahn DH, Murad MH, Bekaii-Saab T. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis. JAMA Oncol. 2020 Dec 1;6(12):e204930. doi: 10.1001/jamaoncol.2020.4930. Epub 2020 Dec 10. PubMed 33090186 ↗
  • Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745. PubMed 32402160 ↗
  • Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Ma N, Nicholas A, Wang Y, Li L, Zhu AX, Finn RS. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022 Apr;76(4):862-873. doi: 10.1016/j.jhep.2021.11.030. Epub 2021 Dec 11. PubMed 34902530 ↗
  • Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Van Dao T, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgue A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng AL, Qin S, Galle PR, Ali S, Marcovitz M, Makowsky M, He P, Kurland JF, Negro A, Sangro B. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid. 2022 Aug;1(8):EVIDoa2100070. doi: 10.1056/EVIDoa2100070. Epub 2022 Jun 6. PubMed 38319892 ↗
  • Hou JP, Shi YB, Fu YF, Li H. I-125 seeds insertion with TACE for advanced HCC: a meta-analysis of randomized controlled trials. Minim Invasive Ther Allied Technol. 2022 Aug;31(6):848-855. doi: 10.1080/13645706.2022.2033786. Epub 2022 Feb 2. PubMed 35107390 ↗
  • Senthilnathan S, Memon K, Lewandowski RJ, Kulik L, Mulcahy MF, Riaz A, Miller FH, Yaghmai V, Nikolaidis P, Wang E, Baker T, Abecassis M, Benson AB 3rd, Omary RA, Salem R. Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: analyzing patterns of progression in 285 patients. Hepatology. 2012 May;55(5):1432-42. doi: 10.1002/hep.24812. Epub 2012 Apr 4. PubMed 22109811 ↗
  • Lazzaro A, Hartshorn KL. A Comprehensive Narrative Review on the History, Current Landscape, and Future Directions of Hepatocellular Carcinoma (HCC) Systemic Therapy. Cancers (Basel). 2023 Apr 27;15(9):2506. doi: 10.3390/cancers15092506. PubMed 37173972 ↗
  • Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021 Jan 21;7(1):6. doi: 10.1038/s41572-020-00240-3. PubMed 33479224 ↗
  • Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19. PubMed 34801630 ↗
  • Vogel A, Martinelli E; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org; ESMO Guidelines Committee. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol. 2021 Jun;32(6):801-805. doi: 10.1016/j.annonc.2021.02.014. Epub 2021 Mar 5. No abstract available. PubMed 33716105 ↗
  • Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, Jou JH, Kulik LM, Agopian VG, Marrero JA, Mendiratta-Lala M, Brown DB, Rilling WS, Goyal L, Wei AC, Taddei TH. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023 Dec 1;78(6):1922-1965. doi: 10.1097/HEP.0000000000000466. Epub 2023 May 22. No abstract available. PubMed 37199193 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Apr 2028, 23 months after the start.

Of 352 non-industry phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's planned 23 months is below that.

Counting every sponsor, half of 432 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2026
First posted
Mar 25, 2026
StartActual
May 14, 2026
Primary completionEst.
Apr 27, 2028
CompletionEst.
Apr 27, 2029
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07493668
Lead sponsor
CHA University
Responsible party
Hong Jae Chon (Principal Investigator, CHA University) — Principal investigator
First posted
Mar 25, 2026
Start date
May 14, 2026
Primary completion
Apr 27, 2028 (estimated)
Completion
Apr 27, 2029 (estimated)
Last update
May 22, 2026

Study contacts

Hong Jae Chon, MD, PhD
Contact
hongjaechon@gmail.com
82-31-780-3928

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion